1 / 40

Infection VIH et Cancer Bronchique

Infection VIH et Cancer Bronchique. Le cancer bronchique en France. 25 000 nouveaux cas par an 5 hommes/1 femme; age moyen 60 ans > 80 % cas liés au tabac 85 % CB non à petites cellules 2 malades sur 3 forme étendue/métastatique < 15 % malades guéris

shandra
Download Presentation

Infection VIH et Cancer Bronchique

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Infection VIH et Cancer Bronchique

  2. Le cancer bronchique en France • 25 000 nouveaux cas par an • 5 hommes/1 femme; age moyen 60 ans • > 80 % cas liés au tabac • 85 % CB non à petites cellules • 2 malades sur 3 forme étendue/métastatique • < 15 % malades guéris • 1ére cause de mortalité par cancer pour les deux sexes confondus ; première cause chez la femme aux USA !

  3. Survie en fonction du stade TNM • % de survie à 5 ans (Mountain 1997) pTNM 67 57 55 39 23 - - cTNM 61 38 34 24 13 5 1 Stade IA Stade IB Stade IIA Stade IIB Stade IIIA Stade IIIB Stade IV N0 N1 mN2 : 29 cN2 : 7 N2 N3

  4. Traitements et stade TNM • Les standards thérapeutiques actuels Stades IA, IB (N0) Stade IIA, IIB (N1) Stade IIIA (N2) Stade IIIB (N3) Stade IV (M1) Chirurgie* + CT péri-opératoire ± curage médiastinal ± RT** post-op. modes d’administration doses, fractionnement CT-RT° ± CT standards CT de 2éme ligne/Tarceva® BSC CT(ddp)°° ± *sauf inopérable, **toujours T3 pariétal, °sauf certains T4, IIIB pleurale et IRC, °°sauf métastase cérébrale ou surrénale unique J Clin Oncol 1997, 15:2996; SOR-FNLCC 2003

  5. Which questions to be answered ? • Is there an excess of risk ? • Is there a specific clinical presentation ? • Is there a particular histological type ? • Is there a poorer prognosis ? • Is there a particular therapeutic management ?

  6. Kaposi sarcoma 94 Atypical mycobacteria 98 Non Hodgkin lymphoma P. carinii pneumonia Liver disease Coronaropathy Cancer 0 5 10 15 20 % Excess of risk of LC in HIV • Increase in cancer-related death in HIV Louie, JID 2002

  7. 93-96 Kaposi sarcoma 96-99 Atypical mycobacteria Bacterial pneumonia P. carinii pneumonia Other opportunistic infection Lung cancer 30 % 0 5 10 15 20 Excess of risk of LC in HIV • Increase of LC in HIV hospitalized patients Dufour, Lung 2004

  8. Frish 302,834 R yes 4 no Parker 26,181 R yes 6.5 no Grulich 31,616 R yes 3.8 no Dal Maso 60,421 R yes 2.4 no Herida 77,025 P yes 1 yes 2 Bower 8640 R yes 1 yes 8.93 Excess of risk of LC in HIV Author • Pre-HAART epidemiological studies n HIV Study Pre-HAART SIR* Post-HAART SIR* Reviewed in Lavolé, Lung Cancer 2005. *SIR is defined by the number of LC observed in the HIV-population/number of LC expected in the general population matched for age

  9. Excess of risk of LC in HIV • Bias due to difference of smoking habits in HIV ? • risk factors for cardiovascular disease • age 35 to 44 years old • HIV patients, n=274 (APROCO cohort) • non HIV-persons, n=1038 (WHO-MONICA project) % of smokers 57 HIV Non HIV 33 Savès, CID 2003

  10. Excess of risk of LC in HIV • Bias due to difference of smoking habits in HIV subgroups ? Groups All Men Women Homosexual IVDU Heterosexual Frish SIR 4.5 4.3 7.1 3.7 6.8 4.2 Dal Maso SIR 2.4 2.2 8.7 - 9.4 - Herida SIR 1 1.13 1.08 0.92 3.16 0.99 Frish, JAMA 2001, Dal Maso, Brit J Cancer 2003; Herida, J Clin Oncol 2003

  11. SIR = 2.5 Excess of risk of LC in HIV • Bias due to difference of smoking habits in HIV • expected number of LC in the general population if 100 % of the persons were smokers 40 40 SIR = 6.5 30 30 LC observed in HIV Number of LC Number of LC 20 20 LC expected in HIV 10 10 0 0 unknown % of smokers 100 % of smokers Parker, Chest 1998

  12. Excess of risk of LC in HIV Author • Pre-HAART epidemiological studies n HIV Study Pre-HAART SIR* Post-HAART SIR* Frish 302,834 R yes 4 no Parker 26,181 R yes 6.5 no Grulich 31,616 R yes 3.8 no Dal Maso 60,421 R yes 2.4 no Herida 77,025 P yes 1 yes 2 Bower 8640 R yes 1 yes 8.93 Reviewed in Lavolé, Lung Cancer 2005. *SIR is defined by the number of LC observed in the HIV-population/number of LC expected in the general population matched for age

  13. Excess of risk of LC in HIV • Increase of LC since the use of HAART • bias due to dramatic decrease in AIDS-related mortality Kaposi sarcoma 94 Atypical mycobacteria 98 Non Hodgkin lymphoma P. carinii pneumonia Liver disease Coronaropathy Cancer 0 5 10 15 20 % Louie, JID 2002

  14. 25000 16395 23152 + 41 % 20000 7 15000 5 Incidence 4591 + 182 % SIR of LC 10000 3 1629 5000 1 0 1980 1985 1990 1995 2000 Years Male Female Excess of risk of LC in HIV • Dramatic increase of LC in HIV-women since the use of HAART Bias due to smoking epidemic in women ? Hérida, J Clin Oncol 2004, Remontet, Resp 2003

  15. Excess of risk of LC in HIV • Hypothesies for causal factors… • increased frequency of smoking in HIV population, but intensity and duration not different • HIV status seems probable, but the mechanisms remain unknown : • degree of immune deficiency • duration of immune deficiency • oncogenic role of HIV per se • other oncogenic virus • role of HAART Cadranel, Respiration 1999; Bower, AIDS 2004

  16. Normal Hyperplasia Metaplasia Dysplasia Carcinoma Excess of risk, which mechanisms Smoking + HIV + ID + HAART… 3p LOH, microsatellite alterations 9p21 LOH telomerase upregulation, MYC over expression 8p21-23 LOH neoangiogenesis, loss of FHIT, P53 mutations, aneuploidy, methylation 5q21 APC-MCC LOH, K-ras 12 mutation Increase of genomic instability ? Wistuba, JAMA 1997

  17. Alshafie Sridhar Vyzula Tirelli 11 19 16 36 49.7 48 44.5 38 82 100 94 89 90 84 100 94 - - - - - 60 py 30 py 40 cig/dy Clinical presentation of LC in HIV Lavolé Spano • Epidemiological characteristics n 44 44 age 42 42 % male 93 93 % smoker 100 100 . duration 28 28 . quantity 30 py 30 py Br J Sur 1984; Chest 1992; Lung Cancer 1996; Cancer 2000; Lung Cancer 2003; Med Oncol 2004

  18. Clinical presentation of LC in HIV Alshafie Sridhar Vyzula Tirelli Lavolé Spano • Epidemiological characteristics n 11 19 16 36 44 44 age 49.7 48 44.5 38 42 42 % male 82 100 94 89 93 93 % smoker 90 84 100 94 100 100 . duration - - - - 28 28 - . quantity 60 py 30 py 40 cig/dy 30 py 30 py Br J Sur 1984; Chest 1992; Lung Cancer 1996; Cancer 2000; Lung Cancer 2003; Med Oncol 2004

  19. Clinical presentation of LC in HIV Alshafie Sridhar Vyzula Tirelli Lavolé Spano • Epidemiological characteristics n 11 19 16 36 44 44 age 49.7 48 44.5 38 42 42 % male 82 100 94 89 93 93 % smoker 90 84 100 94 100 100 . duration - - - - 28 28 - . quantity 60 py 30 py 40 cig/dy 30 py 30 py Br J Sur 1984; Chest 1992; Lung Cancer 1996; Cancer 2000; Lung Cancer 2003; Med Oncol 2004

  20. 100 80 SCC Other 60 % of total LC 40 SC 20 ADC 0 Alshafie Sridhar Vyzula Tirelli Lavolé Spano Clinical presentation of LC in HIV • Histological type Br J Sur 1984; Chest 1992; Lung Cancer 1996; Cancer 2000; Lung Cancer 2003; Med Oncol 2004

  21. Clinical presentation of LC in HIV • No ADC predominance compared to controls 50 Non HIV % of adenocarcinoma 25 HIV 0 Alshafie Vyzula Tirelli Lavolé Br J Sur 1984; Chest 1992; Cancer 2000; Lung Cancer 2003

  22. Clinical presentation of LC in HIV • Extensive disease at presentation

  23. 100 80 Stage I 60 Stage II % of total 40 Stage III Stage IV 20 0 Spano Alshafie Sridhar Vyzula Tirelli Lavolé Clinical presentation of LC in HIV • Clinical TNM staging at presentation Br J Sur 1984; Chest 1992; Lung Cancer 1996; Cancer 2000; Lung Cancer 2003; Med Oncol 2004

  24. Clinical presentation of LC in HIV • % of stage IIIB-IV similar as controls 100 80 60 Non HIV % of stadge III-IV HIV 40 20 0 Alshafie Sridhar Vyzula Tirelli Lavolé Br J Sur 1984; Chest 1992; Lung Cancer 1996; Cancer 2000; Lung Cancer 2003

  25. Clinical presentation of LC in HIV • Almost all heavy smokers • Male predominance (but also male predominance in HIV population of industrialized countries) • Similar to LC in the general population matched for age • Characteristics of LC in HIV-patients are those observed in young people • adenocarcinoma predominance • extensive disease at diagnosis

  26. Survival of LC in HIV • Clinical studies on survival Powles VIH/non VIH 4/4 mo. ns 11/22% - Vyzula VIH/non VIH 8/12.5 mo. p=0.003 10/50% 0/18% Tirelli VIH/non VIH 5/10 mo. p=0.0001 10/48% 0/25% Lavolé VIH/non VIH 9/13 mo. p=0.01 33/55% 13/34% Alshafie VIH/non VIH 4/7 mo. p=0.003 0/20% 0/8% Sridhar VIH/non VIH 3/10 mo. p=0.002 0/32% 0/0% Median 1-yr survey 2-yr survey Br J Sur 1984; Chest 1992; Lung Cancer 1996; Cancer 2000; Lung Cancer 2003; Br J Cancer 2003

  27. Classical factors… Other factors ? ? Prognostic factors on survival TNM: RR=2.2 IC95% [1.3-3.9] PS: RR=11 IC95% [3.6-34] HIV: RR=1.7 IC95% [1-2.9] Lavolé, in press 2004

  28. Non HIV Prognostic factors on survival • Difference in TNM staging at presentation 100 80 60 % of stadge III-IV HIV 40 20 0 Alshafie Sridhar Vyzula Tirelli Lavolé Br J Sur 1984; Chest 1992; Lung Cancer 1996; Cancer 2000; Lung Cancer 2003

  29. Prognostic factors on survival • Difference in PS at presentation p < 0,01 100 75 PS < 2 % of patients 50 PS 2-4 25 0 HIV Non HIV Maybe at cause ? Lavolé, in press 2004

  30. Prognostic factors on survival • Impact of HIV-status • severity of immune deficiency, not demonstrated • duration of immune deficiency, not evaluated • role of HAART, not evaluated • surmortality due to HIV-related mortality ? • impact of LC treatment ? Br J Sur 1984; Chest 1992; Lung Cancer 1996; Cancer 2000; Lung Cancer 2003

  31. Prognostic factors on survival • Surmortality due to HIV-related mortality… 100 HAART 75 Others % of total mortality 50 HIV Lung cancer 25 0 Alshafie Tirelli Lavolé Very unprobable ? Chest 1992; Br J Sur 1984; Lung Cancer 2003

  32. Therapeutic management • Surgical management • absence of large series • similar indications that for the general population, but surgery is less frequently performed in HIV-patients because of poorer PS (64 % vs 100 %, p<0.04) • absence of post-operative surmortality • Radiation management • few case-reports • increase frequency of radiation esophagitis ? Massera, Lung Cancer 2000; Lavolé, in press; Cooper, JAMA 1984; Costleigh, AmJGastro 1995; Vallis, Lancet 91

  33. Therapeutic management • Medical management • absence of prospective studies evaluating efficiency or toxicity of chemotherapy for LC in HIV-patients • indications and drugs similar as for the general population, but CT is less frequently performed in HIV-patients because of poorer PS (71 % vs 100 %, p=0.009) • disease control is less frequent (25 % vs 50 %, p<0.01) and grade III hematological toxicities more comon (75 % vs 25 %, p=0.02) Lavolé, Lung Cancer 2005

  34. Therapeutic management • Interactions between CT and HAART NRTI ddc, ddi, d4T Antiproteases RT, SQ, IND NRTI AZT anemia neutropenia CYP450 neuropathy Anthracyclines Alcaloïdes Taxanes Cyclophosphamide Etoposide Carboplatine Taxanes Cisplatine Vinorelbine Washington, J AIDS Hum Retrovirol 1998; Flexner NEJM 1998; Scagliotti JCO 2002

  35. HIV-related Lung Cancer • How to improve these results ? • to better inform the HIV-population and to encourage smoking cessation • to propose a chest X ray in very large clinical situations and maybe to include HIV-populations in CT-scan screening studies • to open a national database on HIV-related LC • to perform prospective clinical studies evaluating effectiveness and toxicity of chemotherapy in HIV-patients

  36. HIV-related Lung Cancer… a Growing Concern… Jacques Cadranel and Armelle Lavolé Service de Pneumologie et Réanimation Respiratoire UPRES EA3493 Hôpital Tenon, Paris - Université Paris VI

  37. Lung tumors in HIV Kaposi’s sarcoma . RR = 177 . Role of HHV8 Lymphoma . RR = 44-77 . Role of EBV Lung carcinoma . RR = ? . Oncogenic virus ? Cadranel, Respiration 1999

  38. Pre-test : question #1 • Which of the following statements are true concerning the epidemiology of lung cancer in the HIV-population ? • A. LC is more frequent in the HIV-population • B. Increase of LC is more obvious in HIV-women than men • C. LC in the HIV-population is as frequent as in the non HIV-population matched for age • D. LC in HIV-population is as frequent as in non HIV-population matched for smoking habits • E. LC has increased in the HIV-population since the use of HAART

  39. Pre-test : question #2 • Which of the following statements are true concerning the clinical presentation of lung cancer in HIV-patients ? • A. Adenocarcinoma is the most frequent histology • B. One third of patients are non smokers • C. Most patients are PS < 2 • D. Disease is most frequently diagnosed at stage I-IIIA • E. Immunodeficiency is usually severe

  40. Pre-test : question #3 • Which of the following statements are true concerning the prognosis and treatment of lung cancer in HIV-patients ? • A. Prognosis is poorer than in non HIV-patients • B. Poorer prognosis is related to more extensive disease • C. Poorer prognosis is related to the use of less optimal treatment compared with non HIV-patients • D. Chemotherapy is less effective in HIV-patients • E. Post-operative mortality is increased in HIV-patients

More Related